Emergent BioSolutions akcijos akcijų analizė | Akcijų kaina | Naujienos | EBS | US29089Q1058 | A0LC2W

Data	Emergent BioSolutions Akcijų kaina
2024-09-18	6,90 undefined
2024-09-17	6,88 undefined
2024-09-16	7,25 undefined
2024-09-13	7,87 undefined
2024-09-12	7,63 undefined
2024-09-11	7,57 undefined
2024-09-10	7,77 undefined
2024-09-09	7,68 undefined
2024-09-06	7,52 undefined
2024-09-05	7,63 undefined
2024-09-04	7,39 undefined
2024-09-03	7,39 undefined
2024-08-30	8,31 undefined
2024-08-29	8,91 undefined
2024-08-28	8,91 undefined
2024-08-27	9,28 undefined
2024-08-26	9,32 undefined
2024-08-23	9,53 undefined
2024-08-22	9,50 undefined
2024-08-21	10,49 undefined

Data	Emergent BioSolutions Pajamos	Emergent BioSolutions EBIT	Emergent BioSolutions Pelnas
2029e	999,90 mln. undefined	0 undefined	0 undefined
2028e	789,62 mln. undefined	11,21 mln. undefined	−2,14 mln. undefined
2027e	761,34 mln. undefined	12,63 mln. undefined	−2,14 mln. undefined
2026e	1,15 mlrd. undefined	−95,95 mln. undefined	−65,20 mln. undefined
2025e	1,15 mlrd. undefined	−70,70 mln. undefined	−61,45 mln. undefined
2024e	1,12 mlrd. undefined	−35,65 mln. undefined	−109,02 mln. undefined
2023	1,05 mlrd. undefined	−201,50 mln. undefined	−760,50 mln. undefined
2022	1,12 mlrd. undefined	−163,30 mln. undefined	−211,60 mln. undefined
2021	1,77 mlrd. undefined	383,10 mln. undefined	219,50 mln. undefined
2020	1,56 mlrd. undefined	480,10 mln. undefined	305,10 mln. undefined
2019	1,11 mlrd. undefined	114,10 mln. undefined	54,50 mln. undefined
2018	782,40 mln. undefined	89,80 mln. undefined	62,70 mln. undefined
2017	560,90 mln. undefined	124,30 mln. undefined	82,60 mln. undefined
2016	488,80 mln. undefined	105,50 mln. undefined	51,80 mln. undefined
2015	489,30 mln. undefined	141,50 mln. undefined	62,90 mln. undefined
2014	404,50 mln. undefined	89,20 mln. undefined	36,70 mln. undefined
2013	312,70 mln. undefined	45,60 mln. undefined	31,10 mln. undefined
2012	281,90 mln. undefined	39,60 mln. undefined	23,50 mln. undefined
2011	273,40 mln. undefined	34,60 mln. undefined	23,00 mln. undefined
2010	286,20 mln. undefined	76,90 mln. undefined	51,70 mln. undefined
2009	234,80 mln. undefined	40,20 mln. undefined	31,10 mln. undefined
2008	178,60 mln. undefined	29,90 mln. undefined	20,70 mln. undefined
2007	182,90 mln. undefined	33,10 mln. undefined	22,90 mln. undefined
2006	152,70 mln. undefined	38,50 mln. undefined	22,80 mln. undefined
2005	130,70 mln. undefined	37,90 mln. undefined	15,80 mln. undefined
2004	83,50 mln. undefined	13,00 mln. undefined	11,50 mln. undefined

	Pajamos	EBIT	Pelnas
2004	83,50 mln. USD	13,00 mln. USD	11,50 mln. USD
2005	130,70 mln. USD	37,90 mln. USD	15,80 mln. USD
2006	152,70 mln. USD	38,50 mln. USD	22,80 mln. USD
2007	182,90 mln. USD	33,10 mln. USD	22,90 mln. USD
2008	178,60 mln. USD	29,90 mln. USD	20,70 mln. USD
2009	234,80 mln. USD	40,20 mln. USD	31,10 mln. USD
2010	286,20 mln. USD	76,90 mln. USD	51,70 mln. USD
2011	273,40 mln. USD	34,60 mln. USD	23,00 mln. USD
2012	281,90 mln. USD	39,60 mln. USD	23,50 mln. USD
2013	312,70 mln. USD	45,60 mln. USD	31,10 mln. USD
2014	404,50 mln. USD	89,20 mln. USD	36,70 mln. USD
2015	489,30 mln. USD	141,50 mln. USD	62,90 mln. USD
2016	488,80 mln. USD	105,50 mln. USD	51,80 mln. USD
2017	560,90 mln. USD	124,30 mln. USD	82,60 mln. USD
2018	782,40 mln. USD	89,80 mln. USD	62,70 mln. USD
2019	1,11 mlrd. USD	114,10 mln. USD	54,50 mln. USD
2020	1,56 mlrd. USD	480,10 mln. USD	305,10 mln. USD
2021	1,77 mlrd. USD	383,10 mln. USD	219,50 mln. USD
2022	1,12 mlrd. USD	−163,30 mln. USD	−211,60 mln. USD
2023	1,05 mlrd. USD	−201,50 mln. USD	−760,50 mln. USD
2024e	1,12 mlrd. USD	−35,65 mln. USD	−109,02 mln. USD
2025e	1,15 mlrd. USD	−70,70 mln. USD	−61,45 mln. USD
2026e	1,15 mlrd. USD	−95,95 mln. USD	−65,20 mln. USD
2027e	761,34 mln. USD	12,63 mln. USD	−2,14 mln. USD
2028e	789,62 mln. USD	11,21 mln. USD	−2,14 mln. USD
2029e	999,90 mln. USD	0 USD	0 USD

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

6,80	36,30	76,40	105,70	91,50	102,90	171,00	145,90	141,70	179,30	280,50	308,30	271,50	178,30	112,20	167,80	621,30	576,10	642,60	111,70
18,60	2,50	43,30	18,80	24,90	54,90	39,30	74,20	96,00	60,60	58,80	113,90	138,50	143,70	262,50	270,70	272,00	274,70	159,20	191,00
0	0,80	0,90	0	10,00	12,50	8,80	9,50	0	5,60	1,40	6,60	10,00	2,40	8,60	4,60	0	0	0	0
13,30	16,40	24,70	16,90	18,30	13,50	12,70	14,70	15,20	14,60	65,70	60,90	74,00	142,80	205,80	222,50	307,00	350,80	350,70	328,90
1,80	3,10	2,00	2,90	8,20	9,90	11,70	10,30	10,50	12,90	25,80	47,80	16,20	18,20	31,70	20,60	−4,40	70,50	57,90	47,90
0,04	0,06	0,15	0,14	0,15	0,19	0,24	0,25	0,26	0,27	0,43	0,54	0,51	0,49	0,62	0,69	1,20	1,27	1,21	0,68
27,30	30,60	78,20	110,20	124,70	131,80	152,70	209,00	241,80	264,20	314,00	327,80	376,40	407,20	510,20	567,00	675,10	828,40	837,00	399,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	51,40	51,40	41,80	71,90	119,00	41,50	33,90	119,60	811,60	741,90	663,10	604,60	728,80	566,60
0	0	0	0	0	0	5,00	5,50	5,50	14,00	52,60	41,00	41,00	49,10	259,70	266,60	266,70	224,90	218,20	0
1,30	10,60	12,70	19,00	13,20	19,00	47,70	26,60	11,80	3,40	21,00	89,80	8,60	8,90	27,10	65,60	82,40	29,00	171,90	178,10
0,03	0,04	0,09	0,13	0,14	0,15	0,26	0,29	0,30	0,35	0,51	0,50	0,46	0,58	1,61	1,64	1,69	1,69	1,96	1,14
0,07	0,10	0,24	0,27	0,29	0,34	0,50	0,55	0,56	0,63	0,94	1,04	0,97	1,07	2,23	2,33	2,88	2,96	3,17	1,82

100,00	0	0	0	0	0	0	0	0	0	0	0	0	100,00	100,00	100,00	100,00	100,00	100,00	100,00
7,60	34,60	90,90	101,90	109,20	120,50	197,70	220,70	231,00	247,60	274,20	318,00	352,40	618,40	688,60	716,10	784,90	829,40	873,50	904,40
15,30	25,40	48,00	70,30	91,00	122,20	173,90	196,90	220,40	251,50	288,30	351,10	254,50	337,10	367,30	421,80	726,90	957,80	738,70	−21,80
0	−0,30	−0,50	−1,10	−0,90	−1,50	−2,10	−3,30	−4,10	−3,50	−3,00	−2,70	−4,30	−3,70	−5,50	−9,90	−25,30	−16,10	3,10	−5,70
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0,02	0,06	0,14	0,17	0,20	0,24	0,37	0,41	0,45	0,50	0,56	0,67	0,60	0,95	1,05	1,13	1,49	1,77	1,62	0,88
5,50	10,40	27,40	20,30	18,30	17,20	25,40	40,50	31,30	27,50	40,90	38,00	34,60	41,80	80,70	94,80	136,10	128,90	103,50	112,20
5,60	8,80	10,40	11,30	12,80	16,50	25,30	22,10	24,30	25,90	37,90	38,20	40,90	42,70	88,90	105,50	136,90	146,20	128,00	96,20
22,00	9,50	15,10	8,80	1,70	0,30	7,80	3,10	1,80	3,30	14,10	23,40	10,30	15,60	20,70	3,10	77,70	67,10	40,10	29,20
0	0	8,90	11,80	15,00	15,00	0	0	0	0	0	0	20,00	0	0	0	0	0	0	0
1,00	1,40	2,50	3,50	6,20	5,80	17,20	5,40	4,50	0	0	0	0	0	10,10	12,90	33,80	31,60	957,30	413,70
0,03	0,03	0,06	0,06	0,05	0,05	0,08	0,07	0,06	0,06	0,09	0,10	0,11	0,10	0,20	0,22	0,38	0,37	1,23	0,65
11,80	10,50	31,40	42,60	35,90	44,90	30,20	54,10	58,30	62,00	251,00	246,90	248,10	13,50	784,50	798,40	841,00	809,40	448,50	446,50
0	0	0	0	0	0	0	0	0	1,40	0	0	0	0	67,50	63,90	53,20	94,90	59,70	47,20
0,10	0	4,10	4,10	1,50	1,20	20,80	5,00	1,90	17,40	41,60	31,00	20,00	44,30	166,10	160,20	157,50	61,90	41,50	28,90
0,01	0,01	0,04	0,05	0,04	0,05	0,05	0,06	0,06	0,08	0,29	0,28	0,27	0,06	1,02	1,02	1,05	0,97	0,55	0,52
0,05	0,04	0,10	0,10	0,09	0,10	0,13	0,13	0,12	0,14	0,39	0,38	0,37	0,16	1,22	1,24	1,44	1,34	1,78	1,17
0,07	0,10	0,24	0,27	0,29	0,34	0,50	0,54	0,57	0,63	0,95	1,04	0,98	1,11	2,27	2,37	2,92	3,11	3,39	2,05

Emergent BioSolutions Bruto marža	Emergent BioSolutions Pelnas-martža	Emergent BioSolutions EBIT marža	Emergent BioSolutions Pelnas-martža
2029e	32,77 %	0 %	0 %
2028e	32,77 %	1,42 %	−0,27 %
2027e	32,77 %	1,66 %	−0,28 %
2026e	32,77 %	−8,31 %	−5,65 %
2025e	32,77 %	−6,15 %	−5,35 %
2024e	32,77 %	−3,18 %	−9,72 %
2023	32,77 %	−19,20 %	−72,48 %
2022	37,98 %	−14,61 %	−18,94 %
2021	57,82 %	21,60 %	12,38 %
2020	67,42 %	30,87 %	19,62 %
2019	60,80 %	10,32 %	4,93 %
2018	58,81 %	11,48 %	8,01 %
2017	65,11 %	22,16 %	14,73 %
2016	73,14 %	21,58 %	10,60 %
2015	78,03 %	28,92 %	12,86 %
2014	74,78 %	22,05 %	9,07 %
2013	80,14 %	14,58 %	9,95 %
2012	83,65 %	14,05 %	8,34 %
2011	84,56 %	12,66 %	8,41 %
2010	83,54 %	26,87 %	18,06 %
2009	80,28 %	17,12 %	13,25 %
2008	80,91 %	16,74 %	11,59 %
2007	77,97 %	18,10 %	12,52 %
2006	84,22 %	25,21 %	14,93 %
2005	75,82 %	29,00 %	12,09 %
2004	63,95 %	15,57 %	13,77 %

	Bruto marža	EBIT marža	Pelnas-martža
2004	63,95 %	15,57 %	13,77 %
2005	75,82 %	29,00 %	12,09 %
2006	84,22 %	25,21 %	14,93 %
2007	77,97 %	18,10 %	12,52 %
2008	80,91 %	16,74 %	11,59 %
2009	80,28 %	17,12 %	13,25 %
2010	83,54 %	26,87 %	18,06 %
2011	84,56 %	12,66 %	8,41 %
2012	83,65 %	14,05 %	8,34 %
2013	80,14 %	14,58 %	9,95 %
2014	74,78 %	22,05 %	9,07 %
2015	78,03 %	28,92 %	12,86 %
2016	73,14 %	21,58 %	10,60 %
2017	65,11 %	22,16 %	14,73 %
2018	58,81 %	11,48 %	8,01 %
2019	60,80 %	10,32 %	4,93 %
2020	67,42 %	30,87 %	19,62 %
2021	57,82 %	21,60 %	12,38 %
2022	37,98 %	−14,61 %	−18,94 %
2023	32,77 %	−19,20 %	−72,48 %
2024e	32,77 %	−3,18 %	−9,72 %
2025e	32,77 %	−6,15 %	−5,35 %
2026e	32,77 %	−8,31 %	−5,65 %
2027e	32,77 %	1,66 %	−0,28 %
2028e	32,77 %	1,42 %	−0,27 %
2029e	32,77 %	0 %	0 %

Data	Emergent BioSolutions Pardavimai vienai akcijai	Emergent BioSolutions EBIT vienai akcijai	Emergent BioSolutions Pelnas vienai akcijai
2029e	18,90 undefined	0 undefined	0 undefined
2028e	14,92 undefined	0 undefined	−0,04 undefined
2027e	14,39 undefined	0 undefined	−0,04 undefined
2026e	21,81 undefined	0 undefined	−1,23 undefined
2025e	21,72 undefined	0 undefined	−1,16 undefined
2024e	21,19 undefined	0 undefined	−2,06 undefined
2023	20,49 undefined	−3,94 undefined	−14,85 undefined
2022	22,31 undefined	−3,26 undefined	−4,22 undefined
2021	32,78 undefined	7,08 undefined	4,06 undefined
2020	28,91 undefined	8,92 undefined	5,67 undefined
2019	21,11 undefined	2,18 undefined	1,04 undefined
2018	15,22 undefined	1,75 undefined	1,22 undefined
2017	11,15 undefined	2,47 undefined	1,64 undefined
2016	9,91 undefined	2,14 undefined	1,05 undefined
2015	10,34 undefined	2,99 undefined	1,33 undefined
2014	8,83 undefined	1,95 undefined	0,80 undefined
2013	8,52 undefined	1,24 undefined	0,85 undefined
2012	7,74 undefined	1,09 undefined	0,65 undefined
2011	7,55 undefined	0,96 undefined	0,64 undefined
2010	8,81 undefined	2,37 undefined	1,59 undefined
2009	7,48 undefined	1,28 undefined	0,99 undefined
2008	5,86 undefined	0,98 undefined	0,68 undefined
2007	6,16 undefined	1,11 undefined	0,77 undefined
2006	6,21 undefined	1,57 undefined	0,93 undefined
2005	5,73 undefined	1,66 undefined	0,69 undefined
2004	4,09 undefined	0,64 undefined	0,56 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2004	4,09 USD	0,64 USD	0,56 USD
2005	5,73 USD	1,66 USD	0,69 USD
2006	6,21 USD	1,57 USD	0,93 USD
2007	6,16 USD	1,11 USD	0,77 USD
2008	5,86 USD	0,98 USD	0,68 USD
2009	7,48 USD	1,28 USD	0,99 USD
2010	8,81 USD	2,37 USD	1,59 USD
2011	7,55 USD	0,96 USD	0,64 USD
2012	7,74 USD	1,09 USD	0,65 USD
2013	8,52 USD	1,24 USD	0,85 USD
2014	8,83 USD	1,95 USD	0,80 USD
2015	10,34 USD	2,99 USD	1,33 USD
2016	9,91 USD	2,14 USD	1,05 USD
2017	11,15 USD	2,47 USD	1,64 USD
2018	15,22 USD	1,75 USD	1,22 USD
2019	21,11 USD	2,18 USD	1,04 USD
2020	28,91 USD	8,92 USD	5,67 USD
2021	32,78 USD	7,08 USD	4,06 USD
2022	22,31 USD	−3,26 USD	−4,22 USD
2023	20,49 USD	−3,94 USD	−14,85 USD
2024e	21,19 USD	0 USD	−2,06 USD
2025e	21,72 USD	0 USD	−1,16 USD
2026e	21,81 USD	0 USD	−1,23 USD
2027e	14,39 USD	0 USD	−0,04 USD
2028e	14,92 USD	0 USD	−0,04 USD
2029e	18,90 USD	0 USD	0 USD

Segmente	2015
Contract development and manufacturing services	-
Contracts and grants	-
Product sales, net	-
Products	-
CDMO services	-
Contract development and manufacturing services	-
Revenue earned during the period arising from manufacturing sale under the terms of a contract	-
Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants	-
Product Sales	-
Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs	72,70 mln. USD
Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare	−1,88 mln. USD
All Other	-

	Contract development and manufacturing services	Contracts and grants	Product sales, net	Products	CDMO services	Contract development and manufacturing services	Revenue earned during the period arising from manufacturing sale under the terms of a contract	Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants	Product Sales	Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs	Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare	All Other
2015	0 USD	0 USD	0 USD	0 USD	0 USD	0 USD	0 USD	0 USD	0 USD	72,70 mln. USD	−1,88 mln. USD	0 USD

Data	Canada	Non-U.S. Government	Other Countries	U.S Government	U.S. Government	United States
2022	148,60 mln. USD	-	82,80 mln. USD	-	-	889,50 mln. USD
2021	-	894,90 mln. USD	-	897,80 mln. USD	-	-
2020	-	566,90 mln. USD	-	988,50 mln. USD	-	-
2019	-	-	431,30 mln. USD	-	-	674,70 mln. USD
2018	-	80,40 mln. USD	-	-	597,60 mln. USD	-

	Canada	Non-U.S. Government	Other Countries	U.S Government	U.S. Government	United States
2018	0 USD	80,40 mln. USD	0 USD	0 USD	597,60 mln. USD	0 USD
2019	0 USD	0 USD	431,30 mln. USD	0 USD	0 USD	674,70 mln. USD
2020	0 USD	566,90 mln. USD	0 USD	988,50 mln. USD	0 USD	0 USD
2021	0 USD	894,90 mln. USD	0 USD	897,80 mln. USD	0 USD	0 USD
2022	148,60 mln. USD	0 USD	82,80 mln. USD	0 USD	0 USD	889,50 mln. USD

	Akcijų skaičius
2004	20,40 mln. Aktien
2005	22,80 mln. Aktien
2006	24,60 mln. Aktien
2007	29,70 mln. Aktien
2008	30,50 mln. Aktien
2009	31,40 mln. Aktien
2010	32,50 mln. Aktien
2011	36,20 mln. Aktien
2012	36,40 mln. Aktien
2013	36,70 mln. Aktien
2014	45,80 mln. Aktien
2015	47,30 mln. Aktien
2016	49,30 mln. Aktien
2017	50,30 mln. Aktien
2018	51,40 mln. Aktien
2019	52,40 mln. Aktien
2020	53,80 mln. Aktien
2021	54,10 mln. Aktien
2022	50,10 mln. Aktien
2023	51,20 mln. Aktien
2024e	51,20 mln. Aktien
2025e	51,20 mln. Aktien
2026e	51,20 mln. Aktien
2027e	51,20 mln. Aktien
2028e	51,20 mln. Aktien
2029e	51,20 mln. Aktien

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2024-06-30	−0,95	−2,32 (−143,06 %)	2024 Q2
2024-03-31	−0,87	0,59 (167,93 %)	2024 Q1
2023-12-31	−0,19	−0,77 (−301,25 %)	2023 Q4
2023-09-30	−0,23	−0,48 (−112,77 %)	2023 Q3
2023-06-30	−0,49	−1,06 (−115,67 %)	2023 Q2
2023-03-31	−1,25	−3,17 (−153,11 %)	2023 Q1
2022-12-31	0,04	−0,31 (−798,20 %)	2022 Q4
2022-09-30	−0,06	−1,27 (−1 938,52 %)	2022 Q3
2022-06-30	0,38	−0,86 (−327,03 %)	2022 Q2
2022-03-31	0,13	0,18 (42,52 %)	2022 Q1
2021-12-31	4,31	4,50 (4,38 %)	2021 Q4
2021-09-30	2,37	−0,36 (−115,18 %)	2021 Q3
2021-06-30	1,56	0,33 (−78,83 %)	2021 Q2
2021-03-31	1,13	1,53 (34,91 %)	2021 Q1
2020-12-31	3,22	3,67 (14,01 %)	2020 Q4
2020-09-30	2,14	2,19 (2,35 %)	2020 Q3
2020-06-30	0,69	1,98 (186,87 %)	2020 Q2
2020-03-31	0,01	0,01 (−0,99 %)	2020 Q1
2019-12-31	1,75	1,57 (−10,37 %)	2019 Q4
2019-09-30	0,91	1,21 (33,69 %)	2019 Q3
2019-06-30	0,17	0,12 (−28,91 %)	2019 Q2
2019-03-31	0,10	−0,13 (−236,55 %)	2019 Q1
2018-12-31	0,66	0,75 (13,81 %)	2018 Q4
2018-09-30	0,59	0,55 (−6,80 %)	2018 Q3
2018-06-30	0,89	1,07 (20,39 %)	2018 Q2
2018-03-31	0,22	−0,03 (−113,40 %)	2018 Q1
2017-12-31	0,71	0,74 (4,92 %)	2017 Q4
2017-09-30	0,42	0,73 (75,44 %)	2017 Q3
2017-06-30	0,26	0,13 (−49,73 %)	2017 Q2
2017-03-31	0,30	0,29 (−3,01 %)	2017 Q1
2016-12-31	0,49	0,74 (51,39 %)	2016 Q4
2016-09-30	0,26	0,58 (119,20 %)	2016 Q3
2016-06-30	−0,17	−0,18 (−3,33 %)	2016 Q2
2016-03-31	−0,07	0,16 (326,31 %)	2016 Q1
2015-12-31	0,71	0,78 (10,33 %)	2015 Q4
2015-09-30	0,55	0,83 (50,34 %)	2015 Q3
2015-06-30	0,18	0,36 (101,79 %)	2015 Q2
2015-03-31	−0,44	−0,50 (−12,51 %)	2015 Q1
2014-12-31	0,69	0,75 (8,40 %)	2014 Q4
2014-09-30	0,53	0,54 (2,82 %)	2014 Q3
2014-06-30	0,32	0,25 (−21,43 %)	2014 Q2
2014-03-31	−0,14	−0,48 (−239,46 %)	2014 Q1
2013-12-31	0,36	0,41 (12,76 %)	2013 Q4
2013-09-30	0,21	0,36 (73,83 %)	2013 Q3
2013-06-30	0,21	0,29 (38,03 %)	2013 Q2
2013-03-31	−0,15	−0,22 (−51,31 %)	2013 Q1
2012-12-31	0,45	0,44 (−2,65 %)	2012 Q4
2012-09-30	0,14	0,18 (27,30 %)	2012 Q3
2012-06-30	0,23	0,21 (−9,60 %)	2012 Q2
2012-03-31	−0,15	−0,02 (86,44 %)	2012 Q1
2011-12-31	0,73	0,78 (7,26 %)	2011 Q4
2011-09-30	0,10	0,04 (−59,39 %)	2011 Q3
2011-06-30	0,35	0,39 (12,46 %)	2011 Q2
2011-03-31	−0,53	−0,61 (−16,15 %)	2011 Q1
2010-12-31	0,67	0,76 (12,64 %)	2010 Q4
2010-09-30	0,53	0,41 (−22,44 %)	2010 Q3
2010-06-30	0,27	0,31 (16,28 %)	2010 Q2
2010-03-31	0,18	0,08 (−54,47 %)	2010 Q1
2009-12-31	0,05	0,13 (176,01 %)	2009 Q4
2009-09-30	0,06	0,03 (−52,46 %)	2009 Q3
2009-06-30	0,30	0,48 (58,42 %)	2009 Q2
2009-03-31	0,13	0,35 (177,12 %)	2009 Q1
2008-12-31	0,02	0,05 (147,52 %)	2008 Q4
2008-09-30	0,18	0,34 (89,63 %)	2008 Q3
2008-06-30	0,23	0,06 (−73,60 %)	2008 Q2
2008-03-31	0,27	0,24 (−11,99 %)	2008 Q1
2007-12-31	0,88	0,93 (5,84 %)	2007 Q4
2007-09-30	−0,03	0,10 (471,75 %)	2007 Q3
2007-06-30	−0,25	−0,17 (32,67 %)	2007 Q2
2007-03-31	0,02	−0,10 (−595,05 %)	2007 Q1
2006-12-31	0,80	1,03 (29,09 %)	2006 Q4

%	Pavadinimas	Akcijos	Pokytis	Data
5,62207 %	The Vanguard Group, Inc.	2 974 638	336 245	2023-12-31
5,43184 %	Charles Schwab Investment Management, Inc.	2 873 984	1 312 934	2023-12-31
5,09275 %	BlackRock Financial Management, Inc.	2 694 572	437 340	2023-12-31
4,01871 %	Two Sigma Investments, LP	2 126 300	23 024	2023-12-31
3,96081 %	Millennium Management LLC	2 095 662	−1 570 717	2023-12-31
3,11329 %	Hotchkis and Wiley Capital Management, LLC	1 647 243	−781 247	2023-12-31
2,24259 %	D. E. Shaw & Co., L.P.	1 186 552	250 034	2023-12-31
2,08899 %	Jacobs Levy Equity Management, Inc.	1 105 285	−203 926	2023-12-31
2,07375 %	Geode Capital Management, L.L.C.	1 097 219	78 184	2023-12-31
2,06150 %	Morgan Stanley & Co. LLC	1 090 738	569 842	2023-12-31
2,00898 %	State Street Global Advisors (US)	1 062 951	−69 004	2023-12-31
10,64387 %	BlackRock Institutional Trust Company, N.A.	5 631 669	202 038	2023-12-31
1,61283 %	Prescott Group Capital Management, LLC	853 349	554 162	2023-12-31
1,57696 %	Assenagon Asset Management S.A.	834 372	651 480	2023-12-31
1,42536 %	BlackRock Investment Management (UK) Ltd.	754 157	265 932	2023-12-31
1,24404 %	Dimensional Fund Advisors, L.P.	658 220	−143 383	2023-12-31
1,17403 %	Qube Research & Technologies Ltd	621 177	621 177	2023-12-31
1,16510 %	Bridgeway Capital Management, LLC	616 457	−252 148	2023-12-31
1,03440 %	Renaissance Technologies LLC	547 300	547 300	2023-12-31
0,97036 %	AQR Capital Management, LLC	513 416	334 298	2023-12-31
0,95112 %	Cubist Systematic Strategies, LLC	503 239	163 545	2023-12-31
0,85128 %	Palisade Capital Management, LLC	450 412	−58 913	2023-12-31
0,81161 %	Columbia Threadneedle Investments (US)	429 424	−13 495	2023-12-31
0,81067 %	Goldman Sachs Asset Management, L.P.	428 926	−51 522	2023-12-31
0,80057 %	BofA Global Research (US)	423 582	100 029	2023-12-31
0,76956 %	Northern Trust Investments, Inc.	407 172	−17 418	2023-12-31
0,66200 %	Kramer (Robert G Sr.)	350 263	212 308	2023-06-09
0,61040 %	Goldman Sachs & Company, Inc.	322 961	174 168	2023-12-31
0,58192 %	Values First Advisors, Inc.	307 892	155 193	2023-12-31
0,51743 %	Group One Trading, L.P.	273 774	83 133	2023-12-31
0,50971 %	Walleye Capital LLC	269 690	227 596	2023-12-31
0,49703 %	Invesco Capital Management LLC	262 980	−7 988	2023-12-31
0,46686 %	Jane Street Capital, L.L.C.	247 017	−393 410	2023-12-31
0,44912 %	BlackRock Investment Management, LLC	237 628	87 519	2023-12-31
0,42225 %	Acadian Asset Management LLC	223 411	150 048	2023-12-31
0,40100 %	PlainsCapital Corporation	212 169	−22 850	2023-12-31
0,39776 %	Connor, Clark & Lunn Investment Management Ltd.	210 454	920	2023-12-31
0,38397 %	UBS Financial Services, Inc.	203 160	113 993	2023-12-31
0,37414 %	Occudo Quantitative Strategies LP	197 960	197 960	2023-12-31
0,36664 %	Los Angeles Capital Management LLC	193 991	32 460	2024-03-31
0,30328 %	DWS Investments UK Limited	160 465	136 205	2023-12-31
0,28993 %	New York State Common Retirement Fund	153 404	−120	2023-12-31
0,28087 %	PGIM Quantitative Solutions LLC	148 610	79 600	2023-12-31
0,26383 %	Barclays Bank PLC	139 595	30 043	2023-12-31
0,25828 %	HSBC Global Asset Management (UK) Limited	136 657	61 524	2023-12-31
0,24729 %	Parametric Portfolio Associates LLC	130 840	56 033	2023-12-31
0,24434 %	BNY Mellon Asset Management	129 279	−763	2023-12-31
0,23405 %	Numeric Investors LLC	123 836	−20 006	2023-12-31
0,22429 %	Degolyer Donald W	118 670	118 670	2023-10-03
0,22429 %	Fowler (Neal Franklin)	118 670	118 670	2023-10-03
0,21483 %	Truist Bank	113 666	3 595	2023-12-31
0,20426 %	Simplex Trading, LLC	108 076	17 667	2023-12-31
0,20185 %	Loomis, Sayles & Company, L.P.	106 800	0	2023-09-30
0,20014 %	Ohio Public Employees Retirement System	105 893	4 775	2023-12-31
0,19717 %	Havey (Adam)	104 324	73 847	2023-06-09
0,19070 %	Fuller & Thaler Asset Management Inc.	100 900	100 900	2024-02-29
0,18287 %	Dynamic Technology Lab Pte. Ltd.	96 758	96 758	2023-12-31
0,18144 %	Seacrest Wealth Management, LLC	96 000	96 000	2024-03-31
0,17379 %	American Century Investment Management, Inc.	91 954	−207 689	2023-12-31
0,16125 %	Dimensional Fund Advisors, Ltd.	85 318	0	2024-01-31
0,16122 %	Rhumbline Advisers Ltd. Partnership	85 302	2 166	2023-12-31
0,15315 %	Point72 Asset Management, L.P.	81 032	−175 923	2023-12-31
0,15073 %	Bank of Montreal Europe PLC	79 753	−395 543	2023-12-31
0,14965 %	Squarepoint Capital LLP	79 181	−508 220	2023-12-31
0,14776 %	Marshall Wace LLP	78 178	−81 602	2023-12-31
0,14155 %	Citadel Advisors LLC	74 894	−1 125 649	2023-12-31
0,13799 %	SEI Investments Management Corporation	73 010	−23 300	2023-12-31
0,12767 %	Engineers Gate Manager, L.P.	67 549	−19 547	2023-12-31
0,12639 %	BlackRock Japan Co., Ltd.	66 871	21 491	2023-12-31
0,12476 %	SG Americas Securities, L.L.C.	66 011	41 712	2023-12-31
0,12109 %	BNP Paribas Securities Corp. North America	64 069	35 869	2023-12-31
0,11428 %	AllianceBernstein L.P.	60 464	−28 191	2023-12-31
0,11250 %	ETF Architect	59 524	5 352	2023-12-31
0,10622 %	Nuveen LLC	56 201	0	2023-12-31
0,10471 %	Jennison Associates LLC	55 400	−3 600	2024-02-29
0,10406 %	Susquehanna International Group, LLP	55 059	−299 006	2023-12-31
0,09354 %	Avantis Investors	49 494	12 304	2024-03-31
0,09203 %	Strei (Katherine)	48 695	−3 073	2023-02-28
0,09138 %	Lindahl (Richard S)	48 347	−42 158	2024-03-26
0,09055 %	Mellon Investments Corporation	47 908	−59 098	2023-12-31
0,08798 %	Principal Global Investors (Equity)	46 551	7 263	2023-12-31
0,08715 %	Sullivan (Louis W)	46 113	−28 415	2024-03-26
0,08676 %	State of Wyoming	45 907	27 976	2023-12-31
0,08462 %	Hauer (Jerome M)	44 771	33 847	2023-05-25
0,08435 %	LSV Asset Management	44 630	44 630	2024-03-31
0,08375 %	Northern Trust Global Investments	44 310	−5 267	2023-12-31
0,07714 %	Ostrum Asset Management	40 815	−253 712	2023-12-31
0,06924 %	Graham Capital Management, L.P.	36 637	23 986	2023-12-31
0,06577 %	PGIM Fixed Income	34 800	34 800	2023-12-31
0,06489 %	JPMorgan Private Bank (United States)	34 333	34 333	2023-12-31
0,06478 %	Hartzel (William)	34 274	−665	2024-04-07
0,06406 %	BlackRock Advisors, LLC	33 894	0	2023-10-31
0,06388 %	Quantbot Technologies, LP	33 800	25 100	2023-12-31
0,06359 %	Alphacrest Capital Management LLC	33 648	22 807	2022-09-30
0,06234 %	IndexIQ Advisors LLC	32 982	−1 385	2023-12-31
0,05811 %	Harsanyi (Zsolt)	30 747	−28 415	2024-03-26
0,05586 %	Virtu Americas LLC	29 556	12 623	2023-12-31
0,05461 %	Invesco Advisers, Inc.	28 896	−3 121	2023-12-31
0,05246 %	OxFORD Asset Management	27 754	27 754	2023-12-31
0,05178 %	MetLife Investment Management, LLC	27 395	0	2023-12-31

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija	Dviejų metų koreliacija
Soligenix	TiekėjasKlientas	0,91	0,86	0,93	0,63	0,78	0,87
Indivior	TiekėjasKlientas	0,88	0,73	-0,20	-0,63	-0,87	-0,84
Humanigen	TiekėjasKlientas	0,76	0,56	0,75	0,35	0,86	0,68
Merck & Co	TiekėjasKlientas	0,73	0,02	-0,68	-0,62	-0,55	-0,38
ChemoMetec	TiekėjasKlientas	0,72	0,64	0,68	-0,06	0,40	-0,76
AstraZeneca	TiekėjasKlientas	0,61	0,69	-0,35	-0,67	-0,63	-0,56
Vaxart	TiekėjasKlientas	0,59	0,68	0,92	0,73	0,84	0,44
Opiant Pharmaceuticals	TiekėjasKlientas	0,20	0,42	0,72	0,71	-0,40	-0,76
GlaxoSmithKline	TiekėjasKlientas	0,16	0,44	-0,53	-0,52	-0,77	-0,49
Aridis Pharmaceuticals	TiekėjasKlientas	0,01	0,47	0,87	0,63	0,83	0,85

What values and corporate philosophy does Emergent BioSolutions represent?

Emergent BioSolutions Inc represents values of integrity, innovation, and dedication to public health. Following their corporate philosophy, they strive to deliver high-quality products and solutions for public health threats. The company focuses on developing, manufacturing, and delivering medical countermeasures for biodefense and emerging infectious diseases. By collaborating with governments, healthcare organizations, and stakeholders worldwide, Emergent BioSolutions Inc aims to protect and enhance the well-being of individuals and communities. With a commitment to scientific expertise and a patient-centered approach, they contribute to the preparedness and response efforts in the face of various health challenges.

In which countries and regions is Emergent BioSolutions primarily present?

Emergent BioSolutions Inc primarily operates in the United States. As a global specialty biopharmaceutical company, the company's headquarters are located in Gaithersburg, Maryland. With a strong presence in the United States, Emergent BioSolutions Inc focuses on developing and manufacturing therapies for public health threats. The company's products are used in various countries and regions worldwide, supporting preparedness and response efforts for biodefense, emerging infectious diseases, and other public health emergencies.

What significant milestones has the company Emergent BioSolutions achieved?

Emergent BioSolutions Inc, a leading biopharmaceutical company, has achieved significant milestones in its journey. Notably, the company received a U.S. FDA licensure for its proprietary BioThrax® vaccine against anthrax, establishing itself as the sole provider of such a critical defense product for the U.S. government. Additionally, Emergent successfully developed and commercialized various medical countermeasures, including Vaccinia Immune Globulin Intravenous (VIGIV) for smallpox treatment and Trobigard® auto-injector for atropine/pralidoxime chloride poisoning. Furthermore, the company obtained FDA approval for its first-in-class narcolepsy therapy, NARCAN® nasal spray. These achievements highlight Emergent BioSolutions Inc's commitment to enhancing public health through innovative solutions and its contributions to epidemic and pandemic preparedness.

What is the history and background of the company Emergent BioSolutions?

Emergent BioSolutions Inc is a renowned pharmaceutical company with a rich history and background. Established in 1998, Emergent is dedicated to developing innovative solutions to address public health threats. Over the years, the company has built a strong reputation for its expertise in biodefense, vaccines, therapeutics, and contract manufacturing services. Emergent BioSolutions has played a crucial role in supplying vaccines and treatments for various diseases, including anthrax, smallpox, and COVID-19. With a commitment to protecting and enhancing global health, Emergent continues to be at the forefront of life-saving medical advancements.

Who are the main competitors of Emergent BioSolutions in the market?

Emergent BioSolutions Inc faces competition from several players in the market. Some of the main competitors of Emergent BioSolutions Inc include companies like Pfizer Inc, GlaxoSmithKline plc, Sanofi SA, and Johnson & Johnson. These companies are also involved in the biopharmaceutical sector and operate in similar areas such as vaccine development, contract manufacturing, and biodefense solutions. However, Emergent BioSolutions Inc has positioned itself as a leader in the industry, particularly due to its expertise in biodefense solutions and its strong portfolio of products and services.

In which industries is Emergent BioSolutions primarily active?

Emergent BioSolutions Inc is primarily active in the biopharmaceutical industry.

What is the business model of Emergent BioSolutions?

The business model of Emergent BioSolutions Inc revolves around being a global specialty biopharmaceutical company. With a focus on developing and manufacturing vaccines and therapeutics, Emergent BioSolutions Inc aims to address public health threats. The company operates through three segments: Vaccines and Anti-Infectives, Contract Development and Manufacturing Organization (CDMO), and Devices. Through partnerships, strategic acquisitions, and government contracts, Emergent BioSolutions Inc has built a strong portfolio of products and capabilities to provide solutions in areas such as infectious diseases, opioid overdose, and weapons of mass destruction.

Koks yra Emergent BioSolutions 2024 KGV?

Emergent BioSolutions KGV yra −3,24.

Koks Emergent BioSolutions 2024 KUV?

Emergent BioSolutions KUV yra 0,32.

Koks yra Emergent BioSolutions AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Emergent BioSolutions yra 2/10.

Koks yra Emergent BioSolutions 2024 pajamų dydis?

tikėtina Emergent BioSolutions pardavimai yra 1,12 mlrd. USD.

Kokia yra Emergent BioSolutions 2024 pelnas?

tikėtina Emergent BioSolutions pelnas yra −109,02 mln. USD.

Ką daro Emergent BioSolutions?

Emergent BioSolutions Inc. is a US biotechnology company based in Gaithersburg, Maryland. They specialize in the development and manufacturing of biological products, including vaccines and antibodies, to combat infectious diseases, as well as medications and products for emergency situations. The company is divided into three business segments: BioDefense, Civilian Emergency Medicine, and Emergent Family of Companies. Each segment focuses on a specific market and has its own products. The BioDefense segment develops and produces vaccines and antibodies used to combat bioterrorist threats such as anthrax, smallpox, and botulism. This includes the BioThrax vaccine, the only FDA-approved anthrax vaccine in the US, as well as anthrax countermeasures such as Anthrasil. In Civilian Emergency Medicine, Emergent offers products for the treatment of acute medical emergencies, including medical devices and diagnostic equipment for rapid testing. In this segment, Emergent also has several partnerships with government agencies and health organizations to provide products needed in natural disasters and other emergencies. The Emergent Family of Companies includes Emergent's acquisitions and partnerships in other areas and niches of biotechnology, including medical device manufacturing and the development of therapies for various indications such as cancer, autoimmune diseases, and infectious diseases. An important focus of Emergent is collaboration with government agencies and international partners. The company has a specialized team that works with various government organizations and institutions in the US and around the world. This gives Emergent access to specialized resources and enables them to develop and produce products that meet the requirements of the respective government agencies and organizations. As a company with a strong focus on research and development, Emergent invests significant amounts in expanding its product pipeline. Future products include vaccines and therapies for HIV, Ebola, and Zika. Emergent primarily markets its products to government agencies and health organizations. However, the company also benefits from the increasing demand for products to combat infectious diseases due to natural disasters or bioterrorist attacks. Overall, Emergent BioSolutions is a key player in the medical and biotech industry, especially in terms of the development and production of biologics. The company's threefold division allows it to operate in various biotechnology niches and constantly expand its product pipeline. Collaboration with government agencies and the ability to quickly respond to changing requirements are crucial factors for the success of Emergent BioSolutions.

Kokia yra Emergent BioSolutions dividendė?

Emergent BioSolutions moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Emergent BioSolutions moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Emergent BioSolutions arba įmonė dividendų nemoka.

Kas yra Emergent BioSolutions ISIN?

Emergent BioSolutions ISIN yra US29089Q1058.

Kas yra Emergent BioSolutions WKN?

Emergent BioSolutions WKN yra A0LC2W.

Kas yra Emergent BioSolutions Tickeris?

Emergent BioSolutions akcijų simbolis yra EBS.

Kiek dividendų moka Emergent BioSolutions?

Per paskutinius 12 mėnesių Emergent BioSolutions išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Emergent BioSolutions tikėtina išmokės dividendus, kurie sudarys 0 USD.

Kokia yra Emergent BioSolutions dividendų grąža?

Emergent BioSolutions šiuo metu yra dydžio dividendų grąža.

Kada Emergent BioSolutions moka dividendus?

Emergent BioSolutions moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra Emergent BioSolutions dividendų išmokėjimas?

Emergent BioSolutions per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Emergent BioSolutions dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Emergent BioSolutions?

Emergent BioSolutions priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Emergent BioSolutions kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Emergent BioSolutions dividendą nuo 2024-09-19, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-19.

Kada Emergent BioSolutions paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-09-19.

Kokia buvo Emergent BioSolutions dividendų suma 2023 metais?

2023 metais Emergent BioSolutions išmokėjo 0 USD dividendų.

Kokia valiuta Emergent BioSolutions moka dividendus?

Emergent BioSolutions dividendai yra mokami USD.

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0,06	0,08	0,13	0,15	0,18	0,18	0,23	0,29	0,27	0,28	0,31	0,40	0,49	0,49	0,56	0,78	1,11	1,56	1,77	1,12	1,05	1,12	1,15	1,15	0,76	0,79	1,00
-	50,91	56,63	16,92	19,74	−2,20	31,46	22,22	−4,55	2,93	11,03	29,49	21,04	−0,20	14,75	39,64	41,43	40,60	14,02	−37,00	−6,09	6,77	2,50	0,52	−34,06	3,68	26,62
60,00	63,86	76,15	84,21	78,02	80,90	80,34	83,57	84,62	83,63	80,13	74,75	77,91	73,16	65,18	58,82	60,76	67,40	57,81	37,96	32,70	-	-	-	-	-	-
0,03	0,05	0,10	0,13	0,14	0,14	0,19	0,24	0,23	0,24	0,25	0,30	0,38	0,36	0,37	0,46	0,67	1,05	1,03	0,42	0,34	0	0	0	0	0	0
7,00	13,00	37,00	38,00	33,00	29,00	40,00	76,00	34,00	39,00	45,00	89,00	141,00	105,00	124,00	89,00	114,00	480,00	383,00	−163,00	−201,00	−35,00	−70,00	−95,00	12,00	11,00	0
12,73	15,66	28,46	25,00	18,13	16,29	17,09	26,57	12,45	13,88	14,42	22,03	28,83	21,52	22,14	11,38	10,31	30,87	21,60	−14,59	−19,16	−3,13	−6,10	−8,23	1,58	1,39	-
4,00	11,00	15,00	22,00	22,00	20,00	31,00	51,00	23,00	23,00	31,00	36,00	62,00	51,00	82,00	62,00	54,00	305,00	219,00	−211,00	−760,00	−109,00	−61,00	−65,00	−2,00	−2,00	0
-	175,00	36,36	46,67	-	−9,09	55,00	64,52	−54,90	-	34,78	16,13	72,22	−17,74	60,78	−24,39	−12,90	464,81	−28,20	−196,35	260,19	−85,66	−44,04	6,56	−96,92	-	-
27,40	20,40	22,80	24,60	29,70	30,50	31,40	32,50	36,20	36,40	36,70	45,80	47,30	49,30	50,30	51,40	52,40	53,80	54,10	50,10	51,20	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
4,00	11,00	15,00	22,00	22,00	20,00	26,00	47,00	16,00	18,00	30,00	36,00	62,00	51,00	82,00	62,00	54,00	305,00	230,00	−223,00	−760,00
1,00	1,00	3,00	4,00	4,00	5,00	5,00	6,00	9,00	11,00	19,00	32,00	35,00	38,00	42,00	62,00	110,00	114,00	123,00	143,00	125,00
0	0	−11,00	1,00	5,00	2,00	5,00	9,00	20,00	3,00	13,00	16,00	3,00	5,00	3,00	8,00	−1,00	−2,00	46,00	−19,00	−8,00
3,00	−4,00	7,00	−33,00	25,00	−21,00	−25,00	23,00	−46,00	−12,00	24,00	13,00	−65,00	−45,00	53,00	−119,00	−42,00	8,00	−156,00	−30,00	−75,00
2,00	0	26,00	0	−3,00	4,00	22,00	20,00	23,00	30,00	21,00	26,00	24,00	22,00	41,00	50,00	93,00	161,00	118,00	110,00	536,00
0	0	0	1,00	3,00	3,00	1,00	2,00	1,00	2,00	2,00	3,00	7,00	8,00	8,00	10,00	34,00	21,00	30,00	33,00	68,00
4,00	0	18,00	2,00	14,00	16,00	15,00	22,00	4,00	6,00	6,00	4,00	28,00	10,00	12,00	14,00	30,00	109,00	71,00	6,00	52,00
11,00	9,00	42,00	−4,00	55,00	7,00	29,00	98,00	12,00	39,00	97,00	112,00	44,00	53,00	208,00	41,00	188,00	536,00	321,00	−34,00	−206,00
−4,00	−17,00	−6,00	−41,00	−44,00	−20,00	−33,00	−22,00	−54,00	−53,00	−42,00	−30,00	−44,00	−76,00	−54,00	−72,00	−96,00	−151,00	−225,00	−359,00	−57,00
−7,00	−18,00	−7,00	−41,00	−44,00	−30,00	−33,00	−23,00	−54,00	−40,00	−67,00	−210,00	−45,00	−76,00	−249,00	−897,00	−96,00	−151,00	−225,00	−381,00	212,00
−3,00	−1,00	0	0	0	−10,00	0	−1,00	0	13,00	−25,00	−179,00	0	0	−195,00	−825,00	0	0	0	−21,00	270,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	11,00	−1,00	30,00	15,00	0	8,00	−18,00	12,00	3,00	0	180,00	2,00	0	−20,00	795,00	13,00	62,00	−35,00	564,00	−543,00
0	0	0	54,00	2,00	3,00	4,00	7,00	10,00	−5,00	6,00	13,00	25,00	17,00	−13,00	15,00	8,00	31,00	−90,00	−77,00	10,00
0	8,00	−5,00	85,00	18,00	9,00	14,00	−9,00	16,00	−1,00	8,00	198,00	33,00	−18,00	−51,00	788,00	−35,00	69,00	−141,00	481,00	−535,00
0	−2,00	−4,00	0	0	6,00	1,00	1,00	−5,00	0	2,00	4,00	5,00	−35,00	−17,00	−22,00	−57,00	−25,00	−15,00	−5,00	−2,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2,00	0	29,00	40,00	29,00	−14,00	11,00	66,00	−25,00	−2,00	37,00	101,00	32,00	−41,00	−93,00	−66,00	55,00	453,00	−45,00	66,00	−530,00
7,00	−7,90	35,80	−45,30	11,40	−13,50	−3,40	76,80	−41,80	−14,20	55,00	81,60	−0,30	−22,80	153,30	−30,30	91,10	385,00	96,10	−393,60	−264,20
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tiesioginiai išleidimai	19 334
Netiesioginės emisijos iš įsigytos energijos	21 099
Tiesioginiai išmetimai iš vertybių grandinės	—
CO₂ emisijos	40 434
CO₂ mažinimo strategija	✅
Anglies energija	❌
Atomkraft	❌
Bandymai su gyvūnais	✅
Pelz & Leder	—
Pesticidai	—
Palmių aliejus	—
Tabakas	❌
Genetinė inžinerija	❌
Klimato koncepcija	—
Tvarioji miškininkystė	—
Perdirbimo nuostatai	❌
Aplinkai draugiška pakuotė	❌
Pavojingosios medžiagos	❌
Degalų sąnaudos ir efektyvumas	❌
Vandens suvartojimas ir efektyvumas	❌

Moterų dalis tarp darbuotojų	48,3
Moterų dalis valdyme	—
Azijietiškų darbuotojų dalis	—
Akcijų dalis Azijos valdyme	12,8
Hispanų/lotynų kilmės darbuotojų dalis	—
Hispanų/latino kilmės vadybos dalis	4,3
Akcijų turimų tamsios odos darbuotojų procentas	—
Juodaodžių valdymo dalis	11,2
Baltųjų darbuotojų dalis	—
Baltųjų valdymo dalis	68,2
Suaugusiųjų turinys	❌
Alkoholis	❌
Ginkluotė	—
Šaunamieji ginklai	❌
Azartiniai lošimai	❌
Karinių sutarčių	❌
Žmogaus teisių koncepcija	✅
Privatumo politika	—
Darbo ir sveikatos apsauga	✅
Katalikiškas	✅

Tvarumo ataskaita	✅
Akcijų turėtojų įtraukimas	❌
Atsiliepimo taisyklės	❌
Kartelio teisė	❌

Birža	Emergent BioSolutions Akcijų kodas
DIUSELDORFAS	ER4.DU
FRANKFURTAS	ER4.F
LONDON	0IGA.L
LONDON STOCK EXCHANGE	0IGA.L
MIUNCHENAS	ER4.MU
NEW YORK	EBS
SIX	ER4.SW

Emergent BioSolutions Akcijų kodas	Emergent BioSolutions FIGI
EBS:US	BBG000GW06J7
EBS:UA	BBG000GW07N0
EBS:UC	BBG000GW0885
EBS:UN	BBG000GW09K9
EBS:UP	BBG000GW09S1
EBS:UB	BBG000GW0BX0
EBS:UT	BBG000GW0CN9
EBS:UM	BBG000GW0D66
EBS:UX	BBG000GW0DD8
EBS:UD	BBG000GW0HR4
EBS:UF	BBG000GW0KR7
EBS:VY	BBG000GW1MR2
EBS:VJ	BBG000GW1P04
EBS:VK	BBG000GW1PM0
ER4:GR	BBG000MGS8G4
ER4:GF	BBG000MGSB86
ER4:GD	BBG000MGSC57
ER4:GS	BBG000MGSDT9
ER4:GM	BBG000MGSF50
ER4:GB	BBG000MGSFV1
ER4:TH	BBG000WGLFM7
ER4:QT	BBG00BNGDG31
EBS1EUR:EO	BBG00BNGDGM0
EBS1EUR:XH	BBG00BNGDGQ6
EBS1EUR:XF	BBG00BNGDGS4
EBS1EUR:XE	BBG00BNGDGV0
EBS1EUR:XJ	BBG00BNGDGW9
EBS1EUR:XL	BBG00BNGDGX8
EBS1EUR:XG	BBG00BNGDGY7
EBS1EUR:XO	BBG00BNGDGZ6
EBS1EUR:XS	BBG00BNGDH39
EBS1EUR:XA	BBG00BNGDH48
EBS1EUR:E1	BBG00BNGDH57
EBS1EUR:XT	BBG00BNGDH66
EBS1EUR:XW	BBG00BNGDH75
EBS1EUR:XU	BBG00BNGDH84
EBS1EUR:XV	BBG00BNGDH93
EBS1EUR:EU	BBG00BNGDHC9
EBS:VF	BBG00DJGCNH3
EBS1EUR:XX	BBG00JN8GDL6
EBS1USD:X2	BBG00JPZ9BL6
EBS1USD:XB	BBG00JPZ9BM5
EBS1USD:XH	BBG00JPZ9BP2
EBS1USD:XF	BBG00JPZ9BR0
EBS1USD:XE	BBG00JPZ9BT8
EBS1USD:XJ	BBG00JPZ9BV5
EBS1USD:XL	BBG00JPZ9BW4
EBS1USD:XG	BBG00JPZ9BX3
EBS1USD:XO	BBG00JPZ9BY2
EBS1USD:XS	BBG00JPZ9C25
EBS1USD:XA	BBG00JPZ9C34
EBS1USD:E1	BBG00JPZ9C43
EBS1USD:XT	BBG00JPZ9C52
EBS1USD:XW	BBG00JPZ9C61
EBS1USD:XU	BBG00JPZ9C70
EBS1USD:XV	BBG00JPZ9C89
EBS1USD:XM	BBG00JPZ9C98
EBS1USD:XQ	BBG00JPZ9CC4
EBS1USD:XX	BBG00JPZ9CD3
EBS1USD:XZ	BBG00JPZ9CF1
EBS1USD:EU	BBG00JPZ9CH9
0IGA:LN	BBG00JVRNK04
EBS1GBX:XS	BBG00KVTPWS9
EBS1GBX:XH	BBG00KVTPWW4
EBS1GBX:XF	BBG00KVTPWY2
EBS1GBX:XE	BBG00KVTPX07
EBS1GBX:XJ	BBG00KVTPX16
EBS1GBX:XL	BBG00KVTPX25
EBS1GBX:XG	BBG00KVTPX34
EBS1GBX:XO	BBG00KVTPX43
EBS1GBX:XA	BBG00KVTPX89
EBS1GBX:E1	BBG00KVTPX98
EBS1GBX:XT	BBG00KVTPXB5
EBS1GBX:XW	BBG00KVTPXC4
EBS1GBX:XU	BBG00KVTPXD3
EBS1GBX:XV	BBG00KVTPXF1
EBS1GBX:XM	BBG00KVTPXG0
EBS1GBX:XQ	BBG00KVTPXJ7
EBS1GBX:XX	BBG00KVTPXK5
EBS1GBX:XZ	BBG00KVTPXL4
EBS1GBX:EU	BBG00KVTPXN2
ER4:SW	BBG00LVD90S0
ER4:BW	BBG00LVD90Z2
EBS:VG	BBG00X1NNQ39
EBS:VP	BBG00X1S3741
ER4:GZ	BBG00XS60L79
ER4:LA	BBG018H8H6W8
ER4:LU	BBG018J249C9

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodasEBS

ISINUS29089Q1058

VVPA0LC2W

Emergent BioSolutions akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Emergent BioSolutions Akcijų istorija

Emergent BioSolutions akcijų apyvarta, EBIT, pelnas US29089Q1058 · A0LC2W

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Emergent BioSolutions Pajamų, pelno ir EBIT istorija.

Emergent BioSolutions Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Emergent BioSolutions Akcijos Maržos US29089Q1058 · A0LC2W

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Emergent BioSolutions Maržų istorija

Emergent BioSolutions akcijos apyvarta, EBIT, pelnas vienai akcijai US29089Q1058 · A0LC2W

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Emergent BioSolutions Pardavimų, pelno ir EBIT istorija vienai akcijai

Emergent BioSolutions akcija ir akcijų analizė

Emergent BioSolutions Pajamos pagal segmentą US29089Q1058 · A0LC2W

Pardavimai pagal segmentą

Pardavimų pagal segmentą apžvalga

Interpretacija ir panaudojimas

Investavimo strategija

Emergent BioSolutions Pajamos pagal segmentą

Emergent BioSolutions Pajamos pagal regioną US29089Q1058 · A0LC2W

Pardavimai pagal segmentą

Apžvalga: pardavimai pagal regioną

Interpretacija ir panaudojimas

Investavimo strategija

Emergent BioSolutions Pajamos pagal segmentą

Emergent BioSolutions vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Emergent BioSolutions įvertinimas pagal istorinį P/E, EBIT ir P/S

Emergent BioSolutions akcijų skaičius US29089Q1058 · A0LC2W

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Emergent BioSolutions Pelno prognozės

Padaryk geriausias savo gyvenimo investicijas
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Akcijų kodas
EBS

ISIN
US29089Q1058

VVP
A0LC2W